Expression of cytokeratin 20 redefines urothelial papillomas of the bladder

Lancet

Volumn 353, Issue 9157, 1999, Pages 974-977

  Harnden, P ^a   Mahmood, N ^a   Southgate, J ^b  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKERATIN 20; IMMUNOMODULATING AGENT; MITOMYCIN C;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER TUMOR; CARCINOMA IN SITU; FEMALE; FOLLOW UP; HUMAN; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECURRENT DISEASE; UROGENITAL TRACT TUMOR;

EID: 0033586387     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)05383-5     Document Type: Article

References (16)

1. WHO. Histological typing of urinary bladder tumours, no 10. Geneva: WHO, 1973.
2. Jordan A.M., Weingarten J., Murphy W.M. Transitional cell neoplasms of the urinary bladder: can biologic potential be predicted from histologic grading? Cancer. 60:1987;2766-2774.
3. Murphy W.M. Urological pathology, 2nd edn. Philadelphia: WB Saunders, 1997.
4. Reuter V.E., Melamed M.R. The lower urinary tract. In: Sternberg S.S. Diagnostic surgical pathology, 2nd edn. New York: Raven Press, 1994.
5. Murphy W.M., Beckwith J.B., Farrow G.M. Tumors of the kidney, bladder and related structures, third series. Washington DC: Armed Forces Institute of Pathology, 1994.
6. Harnden P., Parkinson M.C. Transitional cell carcinoma of the bladder: diagnosis and prognosis. Curr Diag Pathol. 3:1996;109-121.
7. Kiemeny L.A.L.M., Coebergh J.W.W., Koper N.P.et al. Bladder-cancer incidence and survival in the south-eastern part of the Netherlands, 1975-1989. Eur J Cancer. 30A:1994;1134-1137.
8. Harnden P., Eardley I., Joyce A.D., Southgate J. Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol. 78:1996;870-875.
9. Harnden P., Allam A., Joyce A.D., Patel A., Selby P., Southgate J. Cytokeratin 20 expression by non-invasive transitional cell carcinomas: potential for distinguishing recurrent from non-recurrent disease. Histopathology. 27:1995;167-174.
10. Hall R.R., Parmar M.K., Richards A.B., Smith P.H. Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy. BMJ. 308:1994;257-260.
11. Reading J., Hall R.R., Parmar M.K. The application of a prognostic factor analysis for Ta T1 bladder cancer in routine urological practice. Br J Urol. 75:1995;604-607.
12. Kurth K.H., Denis L., Bouffioux C.et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer. 31A:1995;1840-1846.
13. Deming C.L. The biological behaviour of transitional cell papilloma of bladder. J Urol. 63:1950;815-820.
14. Greene L.F., Hanash K.A., Farrow G.M. Benign papilloma or papillary carcinoma of the bladder? J Urol. 110:1973;205-207.
15. Prout G.R.Jr., Barton B.A., Griffin P.P.et al. Treated history of noninvasive grade 1 transitional cell carcinoma. J Urol. 148:1992;1413-1419.
16. Ooms E.C.M., Anderson W.A.D., Alons C.L.et al. Analysis of the performance of pathologists in the grading of bladder tumors. Hum Pathol. 14:1983;140-143.